Banner Health has announced Francisco Arabia, MD, an internationally recognized surgeon and executive leader in thoracic, cardiothoracic vascular and transplant surgery, has joined the organization.Continue reading→

Rapid, non-invasive diagnosis assisted by TGen assay could be used to help detect many types of cancerContinue reading→

Iluminos Therapeutics has licensed new compounds designed to treat neurodegenerative diseases, particularly Alzheimer’s. Travis Dunckley, PhD, Assistant Research Professor at the ASU-Banner Neurodegenerative Disease Research Center helped develop the new therapies with lead inventor, Christopher Hulme, PhD, Professor of Medicinal Chemistry in the UA Department of Pharmacy and Toxicology (formerly at Eli Lilly and Amgen) and Arthur Shaw, post-doctoral research fellow at the time. The compounds were designed and synthesized at the University of Arizona (UA) College of Pharmacy, in collaboration with the Translational Genomics Research Institute (TGEN).Continue reading→

Continue reading→

Through a process known as strand displacement, a tiny walking device composed of DNA moves across a surface in a cartwheeling motion. The new device performed this feat more rapidly than any DNA walker designed to date.Continue reading→

Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autismContinue reading→

LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced, on May 7, 2018, that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (AEM-28 and analogs) for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. LipimetiX is approximately 60%-owned by Capstone Therapeutics Corp. (OTCQB:CAPS).Continue reading→

Precision medicine is one of the fastest growing fields of medicine, turning the “one-size fits all” approach of healthcare on its head. Precision medicine is a specialized area of medicine that integrates genetic and genomic knowledge with data on environmental and lifestyle influences to individualize and refine care of patients and populations.Continue reading→

TUCSON, Ariz. and HUNINGUE, France, May 07, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders.Continue reading→

Critical Path Institute’s Patient-Reported Outcome Consortium announces its second clinical outcome assessment qualification from the US Food and Drug AdministrationContinue reading→